Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Parexel opens its third office in Japan to address rising demands for clinical development and regulation services, and to supplement the capabilities of its Tokyo office which opened in 1997.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Kendle, INC, AAIPharma and ClinTec.
Quintiles has established a joint venture with Health Kare Pharma International (HKPI) and Ramco Import and Export, focused on providing pharmaceutical contract sales and promotional services in Egypt.
Clinical data management is, and will continue to be a key concern for the pharmaceutical industry, according to Susan Bornstein, executive vice president of eClinical solutions, who discussed the issue with Outsourcing-pharma earlier this week.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at PharmaNet, Kendle, Synexus and Gene Logic.
ZRG Partners says there was a “fight for talent” in hiring, firing and vacancies in Q2, with the outsourcing and pharmaceutical sectors battling for employees within regulatory, quality and clinical roles.
A Japanese pharmaceutical company has contracted UK-based Quay Pharma to make trial stocks of two NCEs used to treat genitourinary disorders. One of the products will be entering the first phase of its clinical studies in Europe, while the second is progressing...
Drug industry focus on clinical data quality, cost and speed is key driver for recent growth of Hungarian trials business says patient recruitment specialist Synexus.
Demand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.
While the summer* heat may slow other industries, the outsourcing sector keeps on moving. Oustourcing-pharma rounds up the key developments, featuring LyoTechnica and AspenTech
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments West Pharmaceutical Services, Unilife and ACR Image Metrix.
Demand for biomarker analysis is strong, but the pace of technological change is causing an investment headache for CROs according to a new report by Industry Standard Research (ISR).
Regulus Therapeutics’ microRNA satellite technology has won the firm its biggest deal to date with French drugmaker Sanofi-Aventis agreeing a development accord worth up to $750m (€606m).
French drug maker Sanofi-Aventis continues to spearhead the fight for a more secure pharmaceutical supply chain by launching an anti-counterfeit medication initiative in Egypt.
PhRMA, EFPIA, JPMA and the IFPMA have adopted a “joint position” that calls on member companies to submit summaries of all Phase III studies and those of “significant medical importance” for publication in peer reviewed journals.
The EMA has published its thoughts on monitoring overseas trials and will seek to establish an international network of regulators to develop and implement a robust oversight framework.
Sepha has introduced EZ Blister II to meet rising demand from India, China and South America for an affordable, mobile blister packaging machine for clinical trial use.
US CMO Contract Pharmaceuticals (CPL) to close Buffalo plant by the end of 2011 on weak demand it attributes to pharmaceutical industry outsourcing cuts in downturn.
Contract research organisation (CRO) Chiltern says new Australia and Singapore offices are a natural progression for its contract research business in the Asia-Pacific region.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Quintiles, ClinTec, Novasep, SCM and GVK.
Demand in “Pharmerging” markets will offset declining revenues from off-patent blockbusters and drive prescription drug sales to $1.1tr (€819bn) by 2014, according to IMS Health.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at LAB Research, PBI, CRF Health and US Data Management.
Clinical trials that finish early due to positive treatment effects often have misleading findings, according to a journal paper which recommends researchers resist pressures to end studies prematurely.
Outsourcing-Pharma presents its latest round up of movements in the pharma sector, including appointments at Quintiles, PharmaNet, IGI Laboratories and Sentrx.
The Botswanan government is seeking to initiate local pharma manufacturing, which would lower drug prices, by entering into public-private partnerships (PPP), according to a report by F&S.
Outsourcing to Asia is changing “from a tactical to a strategic imperative” as a result of the region gaining the capabilities needed to perform work high up the biopharma value chain, according to Quintiles.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Pacific Biomarkers, Halloran Consulting Group and Venn Life Sciences.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at GlaxoSmithKline, Synthon, BioSante and Xencor.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including a new management team at a NextPharma site and appointments at Quintiles.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Cel-Sci strengthening its manufacturing team and three promotions at Adolor.
New Jersey, US-based contractors Catalent Pharma Solutions and Compass Pharma Services expanded their respective blister pack offerings last week, both citing growing drug industry demand.
US FDA has missed its review deadline for MannKind’s inhaled insulin candidate Afrezza after failing to complete inspection of third-party contract supplier.
PX'Therapeutics SA, formerly called Protein'eXpert, has set up an additional biomanufacturing unit dedicated to producing therapeutic proteins and monoclonal antibodies in mammalian cells.
Just weeks after completing its billion dollar Wyeth takeover, US drug giant Pfizer has floated the idea of entering Japan’s $5.8bn (€3.9bn)-a-year generic drugs market in 2011 in a bid to further diversify its revenue streams.
